Other languages InDex Pharmaceuticals Holding AB

Equities

INDEX

SE0008966295

Delayed Nasdaq Stockholm Other stock markets 06:37:18 2024-04-29 am EDT			5-day change	1st Jan Change
0.37 ^SEK	+0.54%		+6.02%	+44.53%

Apr. 26	InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 05	Index Pharmaceuticals Holding AB Announces Board Resignations	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26
Index Pharmaceuticals Holding AB Announces Board Resignations	Apr. 05
InDex Pharmaceuticals CEO, CFO to Step Down as Operations Cease	Mar. 26
Index Pharmaceuticals Holding AB Announces Resignation of Johan Giléus as Deputy CEO	Mar. 26
InDex Pharmaceuticals Holding AB Announces Resignation of Jenny Sundqvist as CEO, Effective September 26, 2024	Mar. 26
InDex Pharmaceuticals Launches Strategic Review Amid Decision to Stop Cobitolimod Development	Feb. 27
InDex Pharmaceuticals Holding AB Discontinues the Development of Cobitolimod	Feb. 26
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28
InDex Pharmaceuticals Holding AB Discontinues Cobitolimod Phase III Program	Nov. 21
InDex Pharmaceuticals Holding AB Announces Composition of the Nomination Committee	23-10-30
InDex Pharmaceuticals Holding AB Receives New Patent for Cobitolimod in South Korea	23-10-20
InDex Pharmaceuticals Holding AB Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude	23-10-11
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23
InDex Pharmaceuticals Holding AB Announces Positive Results from the Pharmacokinetic (PK) Study	23-08-22
InDex Pharmaceuticals Holding AB Announces New Formulation Patent for Drug Candidate Cobitolimod Grants by European Patent Office	23-08-02
InDex Pharmaceuticals Obtains New European Patent for Inflammatory Bowel Disease Drug	23-08-02
InDex Pharmaceuticals Holding AB Announces License Agreement with Viatris Japan to Develop and Commercialize Cobitolimod in Japan	23-05-31
InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages InDex Pharmaceuticals Holding AB

Equities

INDEX

SE0008966295

Other languages

Filters